nicotinic acid analog (ARI-3037MO) / Arisaph - LARVOL DELTA

Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: Arisaph Pharmaceuticals Inc

New P2 trial • Atherosclerosis • Biosimilar • Dyslipidemia

REASCEND: Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia (clinicaltrials.gov) - P2; N=176; Active, not recruiting; Sponsor: Arisaph Pharmaceuticals Inc; Recruiting ➔ Active, not recruiting

Enrollment closed • Biosimilar • Dyslipidemia